Loading...

China SXT Pharmaceuticals, Inc.

SXTCNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$2.09
$0.75(55.97%)

China SXT Pharmaceuticals, Inc. (SXTC) Stock Overview

Explore China SXT Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-2.19%
2.19%
Profit Growth
$5.35
47.79%
EPS Growth
$5.35
83.94%
Operating Margin
691.04%
55.15%
ROE
47.36%
47.79%
Dividend Yield
0.00%
Analyst Recommendations data is not available for SXTCAnalyst Recommendations details for SXTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

CEO

Mr. Feng Zhou

Employees

75

Headquarters

178 North Taidong Road, Taizhou

Founded

2019

Frequently Asked Questions